# US 2022/0016055 A1 · Pharmaceutical Compositions For Combination Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016055 A1
- Document ID: US20220016055A1
- Status: Published application
- Kind: A1
- Application number: 17/386,098
- Filed: 2021-07-27
- Published: 2022-01-20
- Earliest claimed: 2012-02-16
- Assignees: Saniona A/S
- Applicants: Saniona A/S
- Inventors: Henrik Bjork Hansen; Morten Grunnet; Bo Hjorth Bentzen; Lars Hyveled-Nielsen; Jorgen Buus Lassen; Claus Sundgreen
- Web page: https://patentgrep.com/patent/US20220016055A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.

## Claims

### Claim 1

A method of inducing hypophagia in a human comprising:
administering 0.1 mg to 1 mg of Tesofensine, or a pharmaceutically acceptable salt thereof, to the human, daily;
in combination with 25 mg to 200 mg of Metoprolol, or a pharmaceutically acceptable salt thereof, daily,
wherein the combination is effective in inducing hypophagia and wherein the combination is effective in preventing or alleviating drug-induced cardiovascular side-effects.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Tesofensine, or pharmaceutically acceptable salt thereof, is administered at a dosage of 0.1 mg to about 0.5 mg daily, based on the amount of free base.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Metoprolol, or pharmaceutically acceptable salt thereof, is administered at a dosage of 25 mg to 100 mg daily, based on the amount of free base.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human is a pre-obese human, an obese human, or a morbidly obese human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the human suffers from over-eating disorders, bulimia nervosa, binge eating disorder, compulsive over-eating, impaired appetite regulation, metabolic syndrome, type 2 diabetes, dyslipidemia, atherosclerosis, or drug-induced obesity.

### Claim 6 (depends on 1)

The method of claim 1, wherein the human suffers from an over-eating disorder, bulimia nervosa, binge eating disorder, or compulsive over-eating.

### Claim 7 (depends on 1)

The method of claim 1, wherein the drug-induced cardiovascular side effects are increased heart rate, increased diastolic blood pressure, or increased systolic blood pressure, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Tesofensine or the pharmaceutically acceptable salt thereof and the Metoprolol or the pharmaceutically acceptable salt thereof are administered separately.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Tesofensine or the pharmaceutically acceptable salt thereof and the Metoprolol or the pharmaceutically acceptable salt thereof are administered in a combined form.

### Claim 10 (depends on 1)

The method of claim 1, wherein the Tesofensin or the pharmaceutically acceptable salt thereof and the Metoprolol or the pharmaceutically acceptable salt thereof are administered orally.

### Claim 11 (depends on 10)

The method of claim 10, wherein the Tesofensin or the pharmaceutically acceptable salt thereof and the Metoprolol or the pharmaceutically acceptable salt thereof are each administered as a tablet or capsule.

### Claim 12 (depends on 1)

The method of claim 1, wherein the human is administered a pharmaceutically acceptable salt of Tesofensine and the pharmaceutically acceptable salt of Tesofensine is Tesofensine citrate.

### Claim 13 (depends on 1)

The method of claim 1, wherein the human is administered a pharmaceutically acceptable salt of Metoprolol and the pharmaceutically acceptable salt of Metoprolol is metoprolol succinate.
